In Conversation

There are about 250 employees and you have regional presence in Latin America. In your view as CEO, can you tell our readers about the biggest…

You came back to Mexico last July- what in your view have been the biggest developments in the Mexican pharmaceutical market since you were last here…

Please can you give us a rundown of Shires activities in Mexico in the last four years, and the key achievements and milestones along the way?…

Please can you give our readers a brief rundown of the major milestones and challenges that you have faced at Octapharma since becoming Managing Director? When…

From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over…

As a promoter and “sales agent” for Bogotá and Colombia can please you take us through the country’s journey over the past decade and how this…

While LatAm originally emerged from the SIPLAS organization, how was it evolved since then to be where it is today? LatAm was born in 2000 as…

The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing main milestones and achievements of the company since you have been…

Novartis’ pharmaceutical activities include innovators, generics and biopharmaceuticals. How has your portfolio developed in Chile? What therapeutic areas is Novartis favoring in the Chilean context? Novartis…

Kampar began its operations in Chile in 2005. What have been the main milestones and achievements of the company in the last five years? Our main…

What have been the main milestones and achievements of the company since it established itself in Chile in 1980? I think our main achievement has been…

IMS was recently acquired by two investment funds, how has this affected the operations of the company and what changes did it bring in the Chilean…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here